Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Inhaled antipseudomonal therapies are critical components in the management of cystic fibrosis (CF) and have significantly contributed to improved patient outcomes. Dry powder inhaler technologies represent a significant advance in drug delivery, alleviating treatment burden and potentially improving adherence associated with traditional CF nebulized therapies. Tobramycin inhalation powder (TIP) uses PulmoSphere(®) technology for very efficient drug delivery into the lower airways. In placebo-controlled and comparative studies with traditional tobramycin formulations, TIP is equally efficacious and is associated with increased patient convenience and satisfaction. TIP has been recommended in the 2013 CF Foundation and the 2014 European guidelines as a therapy in CF for the maintenance of lung health. Going forward, TIP may offer a therapeutic advantage over traditional formulations of tobramycin as recent prospective 'real world' studies of TIP have demonstrated high patient tolerance and improved adherence compared with traditional formulations.